ALKERMES reported $469.56M in Current Liabilities for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
Acadia Pharmaceuticals ACAD:US USD 116.57M 1.11M
Amgen AMGN:US USD 14.33B 1.71B
Biogen BIIB:US USD 3.93B 1.09B
Biomarin Pharmaceutical BMRN:US USD 521.02M 56.29M
Bluebird Bio BLUE:US USD 126.73M 22.13M
Bristol Myers Squibb BMY:US USD 18.93B 1.98B
Coherus Biosciences CHRS:US USD 171.32M 30.56M
Eli Lilly And LLY:US USD 15.65B 32.2M
Gilead Sciences GILD:US USD 10.42B 1.2B
Heron Therapeutics HRTX:US USD 93.88M 15.62M
Intra Cellular Therapies ITCI:US USD 77.41M 6.78M
IONIS PHARMACEUT IONS:US USD 283.45M 15.64M
JAZZ PHA JAZZ:US USD 812.95M 107.51M
Marinus Pharmaceuticals MRNS:US USD 21.05M 2.06M
Minerva Neurosciences NERV:US USD 2.2M 1.21M
Nektar Therapeutics NKTR:US USD 83.99M 21M
Neurocrine Biosciences NBIX:US USD 485.1M 199.4M
Otsuka Holdings 4578:JP JPY 544B 14.63B
Regeneron Pharmaceuticals REGN:US USD 2.88B 154.7M
Revance Therapeutics RVNC:US USD 74.73M 2.49M
Teva Pharmaceutical Industries TEVA:US USD 11.53B 538M
Vertex Pharmaceuticals VRTX:US USD 2.61B 53.1M